Related Experiment Video
Updated: Oct 20, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a
Sandra Shi1, Natalia Gouskova1, Mehdi Najafzadeh2
1Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.
Background:
Restricted mean survival time analysis offers an intuitive and robust summary of treatment effect compared with HRs.
Objective:
To examine the effect of intensive versus standard blood pressure (BP) control on death or cardiovascular events in type 2 diabetes.
Design:
Secondary analysis of the Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial.
Setting:
77 sites in the USA and Canada.
Participants:
4733 adults with type 2 diabetes at high risk for cardiovascular events.
Interventions:
Systolic BP target <120 mm Hg (n=2371) versus <140 mm Hg (n=2362).
Measurements:
Composite endpoint of death, non-fatal myocardial infarction or non-fatal stroke.
Results:
The mean event-free survival time over 5 years (1825 days) was similar between intensive and standard BP control (1716 vs 1714 days; mean difference, 1.3 (95% CI -18.1 to 20.7) days). However, intensive BP treatment was more beneficial for those assigned to standard glycaemic control (1725 vs 1697 days; mean difference, 28.1 (95% CI 0.4 to 55.9) days), but not for those assigned to intensive glycaemic control (1706 vs 1731 days; mean difference, -25.2 (95% CI -52.3 to 1.9) days) (p=0.008 for interaction). In subgroup analysis, the mean event-free survival time difference between intensive and standard BP treatment was -76.0 (95% CI -131.8 to -20.3) days for those with cognitive impairment and 21.8 (95% CI -24.0 to 67.5) days for those with normal cognitive function (p=0.008 for interaction). The effect was not different by age, sex and baseline cardiovascular disease status.
Conclusions:
Intensive BP treatment may reduce death and cardiovascular events among patients with type 2 diabetes receiving standard glycaemic treatment and without cognitive impairment.
Trial Registration Number:
NCT00000620; Post-results.
Related Concept Videos
Comparing the Survival Analysis of Two or More Groups
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

